CONMED CEO granted 28,145 RSUs worth $1M

Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Beyer Pat reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corp President & CEO Pat Beyer received a grant of 28,145 RSUs, representing a $1 million target-value equity award. The RSUs are scheduled to vest over three years in three equal annual tranches starting April 1, 2026, with a two-year post-vest holding period on net after-tax shares. Following this grant, Beyer directly holds 28,145 RSUs tied to CONMED common stock, designed to align compensation with longer-term company performance.

Insider Trade Summary

Grant/Award: 28,145 shares

Grant/Award 1 txn

Insider Beyer Pat

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units)	28,145	$0.00	$0.00

Holdings After Transaction: RSUs (Restricted Stock Units) — 28,145 contracts (Direct)

Footnotes (1)

1. F1. On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event.

Key Figures

RSU grant size: 28,145 RSUs Target award value: $1M Vesting schedule: 3 years, 3 equal annual tranches +3 more

6 metrics

RSU grant size 28,145 RSUs Grant to President & CEO Pat Beyer on April 1, 2026

Target award value $1M Additional equity award approved by Board for CEO

Vesting schedule 3 years, 3 equal annual tranches Vesting begins April 1, 2026

Post-vest holding period 2 years Applied to net after-tax shares after each vesting

RSU expiration April 1, 2036 Expiration date of the RSUs reported

Shares following transaction 28,145 RSUs Total RSUs held directly after grant

Key Terms

RSUs (Restricted Stock Units), target value, post-vest holding period, vest, +1 more

5 terms

RSUs (Restricted Stock Units) financial

"security_title: "RSUs (Restricted Stock Units)""

target value financial

"approved an additional equity award for the CEO of $1M in target value"

post-vest holding period financial

"with a 2-year post-vest holding period to be applied to net after tax shares"

vest financial

"scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

underlying security financial

"underlying_security_title: "Common Stock""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did CONMED (CNMD) CEO Pat Beyer receive?

Pat Beyer received a grant of 28,145 restricted stock units (RSUs) tied to CONMED common stock. The award has a $1 million target value and is structured as part of the CEO’s equity-based compensation package approved by the company’s Board of Directors.

How will the new RSU grant for CONMED (CNMD) CEO vest?

The 28,145 RSUs granted to CONMED’s CEO are scheduled to vest over three years in three equal annual tranches starting April 1, 2026. This multi-year vesting schedule encourages retention and links realized compensation to the company’s performance over time.

Is there a holding requirement on CONMED (CNMD) CEO’s RSU award?

Yes. The RSU award carries a two-year post-vest holding period on net after-tax shares from each vesting event. This means shares that remain after taxes must be held for two additional years, reinforcing longer-term alignment between the CEO and shareholders.

What is the target value of CONMED (CNMD) CEO’s new RSU award?

The Board approved an additional equity award for the CEO with a $1 million target value. This value is delivered entirely in RSUs, which vest annually over three years starting April 1, 2026, subject to the time-based vesting and holding requirements described.

How many RSUs does CONMED (CNMD) CEO hold after this Form 4?

After this transaction, the Form 4 shows Pat Beyer holding 28,145 RSUs directly. These RSUs are convertible into the same number of CONMED common shares upon vesting and settlement, subject to the vesting schedule and post-vest holding requirements disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beyer Pat

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FLORIDA 33773

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	04/01/2026		A		28,145		(1)	04/01/2036	Common Stock	28,145	$0	28,145	D

Explanation of Responses:

1. On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event.

	/s/ Thomas Fistek for Pat Beyer by Power of Attorney	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)